News & Trends - MedTech & Diagnostics
Scaling point-of-care test to combat antimicrobial resistance in ANZ
Antimicrobial resistance (AMR) stands as a critical global threat to public health, primarily driven by the misuse and overuse of antimicrobials, and the development of drug-resistant pathogens. Lumos Diagnostics has taken a significant step in combatting this issue by securing an agreement with Regional Health Care Group (RHCG) in Australia and New Zealand, to distribute their FebriDx point-of-care test.
This test effectively distinguishes between viral and bacterial acute respiratory infections, aiding healthcare professionals in making rapid and accurate treatment decisions.
The collaboration marks an expansion of FebriDx’s reach through Henry Schein’s extensive Medical business network, now encompassing Australia and New Zealand. RHCG, a pivotal arm of Henry Schein, the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, will spearhead the distribution efforts.
Mike Covey, Vice President of Henry Schein for the APAC Region and Managing Director in Australia, stated “At Henry Schein, our goal is to help health care professionals enhance efficiencies through practice care so they can focus on delivering quality patient care. We are therefore delighted to expand our distribution of FebriDx beyond Portugal, Spain, the Netherlands, the United Kingdom, and the United States to now include Australia and New Zealand.”
FebriDx delivers results within 10 minutes from a simple fingerstick blood sample, facilitating swift and accurate management of infectious patients across Primary Care, Urgent Care, Emergency Departments, Paediatric facilities, and other outpatient settings. RHCG has already commenced sales and marketing initiatives to introduce FebriDx across ANZ.
“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said Doug Ward, CEO of Lumos Diagnostics.
“Henry Schein has been a terrific and supportive partner for Lumos across Europe. With our recent U.S. launch and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, to support our customers. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the Australian and New Zealand markets.”
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics
AI-assisted colonoscopy boosts polyp and adenoma detection
MedTech & Diagnostics News: In a standard colonoscopy, as many as one-third of colorectal polyps and adenomas can go by […]
MoreNews & Trends - Pharmaceuticals
‘Every day of delay is costing Australian lives’, says Rare Cancers Australia CEO
Pharma News: Rare Cancers Australia (RCA) has voiced its disappointment alongside the pharmaceutical industry following the Pharmaceutical Benefits Advisory Committee’s […]
MoreNews & Trends - Pharmaceuticals
Government’s silence on Senate report leaves cancer patients in limbo
Pharma News: NeuroEndocrine Cancer Australia has urged the government to respond to the Senate report on equitable access to diagnosis […]
More